Open-Label Phase II Study of Neoadjuvant Bevacizumab Combined with FEC→Paclitaxel in Patients with Inflammatory or Locally Advanced Breast Cancer

被引：0
|
作者：
Venturini, M.
Del Mastro, L.
Aitini, E.
Saracchini, S.
Garrone, O.
Durando, A.
De Placido, S.
Boni, C.
Levaggi, A.
Scalamogna, R.
Galli, A.
Clavarezza, M.
机构：
[1] Osped Sacro Cuore Don Calabria, Negrar, VR, Italy
[2] Ist Nazl Ric Canc, Genoa, Italy
[3] Osped C Poma, Mantua, Italy
[4] Osped S Maria Angeli, Pordenone, Italy
[5] Osped Santa Croce & Carle, Cuneo, Italy
[6] Osped S Anna, Turin, Italy
[7] Univ Naples Federico II, Naples, Italy
[8] Arcispedale Santa Maria Nuova, Reggio Emilia, Italy
[9] Med Affairs, Monza, Italy
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/0008-5472.SABCS10-P1-11-20
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-11-20
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A Phase II Trial of Neoadjuvant Chemotherapy with Genexol® (Paclitaxel) and Epirubicin for Locally Advanced Breast Cancer
    Lee, Jinsun
    Kim, Jeryong
    Chang, Eilsung
    Choi, Woonjung
    Lee, Kwangman
    Yoon, Hyunjo
    Jung, Sunghoo
    Park, Minho
    Yoon, Junghan
    Kim, Sungyong
    JOURNAL OF BREAST CANCER, 2014, 17 (04) : 344 - 349
  • [22] Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study
    Philip, Philip A.
    Lacy, Jill
    Portales, Fabienne
    Sobrero, Alberto
    Pazo-Cid, Roberto
    Manzano Mozo, Jose L.
    Kim, Edward J.
    Dowden, Scot
    Zakari, Ahmed
    Borg, Christophe
    Terrebonne, Eric
    Rivera, Fernando
    Sastre, Javier
    Bathini, Venu
    Lopez-Trabada, Daniel
    Asselah, Jamil
    Saif, Muhammad Wasif
    Li, Jack Shiansong
    Ong, Teng Jin
    Nydam, Thomas
    Hammel, Pascal
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2020, 5 (03): : 285 - 294
  • [23] ATLAS: A Phase II, open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma
    Grivas, Petros
    Teo, Min Yuen
    Vogelzang, Nicholas
    Alva, Ajjai
    Zakharia, Yousef
    Adra, Nabil
    Drakaki, Alexandra
    Hussain, Arif
    Morales-Barrera, Rafael
    Necchi, Andrea
    Rodriguez-Vida, Alejo
    Feyerabend, Susan
    Gupta, Sumati
    Josephs, Debra H.
    Loriot, Yohann
    Srinivas, Sandy
    Wride, Kenton
    Thomas, Daleen
    Dusek, Rachel
    Simmons, Andrew D.
    Nepert, Dale
    Chowdhury, Simon
    CANCER RESEARCH, 2019, 79 (13)
  • [24] A Neoadjuvant, Randomized, Open-Label Phase II Trial of Afatinib Versus Trastuzumab Versus Lapatinib in Patients With Locally Advanced HER2-Positive Breast Cancer
    Rimawi, Mothaffar F.
    Aleixo, Sabina B.
    Alarcon Rozas, Ashley
    de Matos Neto, Joao Nunes
    Caleffi, Maira
    Figueira, Alicardo Cesar
    Souza, Sulene Cunha
    Reiriz, Andre B.
    Gutierrez, Carolina
    Arantes, Heloisa
    Uttenreuther-Fischer, Martina M.
    Solca, Flavio
    Osborne, C. Kent
    CLINICAL BREAST CANCER, 2015, 15 (02) : 101 - 109
  • [25] Neoadjuvant capecitabine plus paclitaxel in gastric cancer patients with liver metastasis: an open-label, uncontrolled, prospective phase II clinical study
    Yuan, P.
    Wu, A.
    Li, Z.
    Tang, L.
    Bu, Z.
    Ren, H.
    Ji, J.
    ANNALS OF ONCOLOGY, 2015, 26 : 63 - 63
  • [26] A phase II study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer
    Villman, Kenneth
    Ohd, John F.
    Lidbrink, Elisabet
    Malmberg, Lena
    Lindh, Birgitta
    Blomqvist, Carl
    Nordgren, Hans
    Bergh, Jonas
    Bergstrom, Daniel
    Ahlgren, Johan
    EUROPEAN JOURNAL OF CANCER, 2007, 43 (07) : 1153 - 1160
  • [27] A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer
    Giampietro Gasparini
    Francesco Torino
    Takayuki Ueno
    Stefano Cascinu
    Teresa Troiani
    Alberto Ballestrero
    Rossana Berardi
    Junichi Shishido
    Akihiko Yoshizawa
    Yukiko Mori
    Satoshi Nagayama
    Paola Morosini
    Masakazu Toi
    Angiogenesis, 2012, 15 : 141 - 150
  • [28] A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer
    Gasparini, Giampietro
    Torino, Francesco
    Ueno, Takayuki
    Cascinu, Stefano
    Troiani, Teresa
    Ballestrero, Alberto
    Berardi, Rossana
    Shishido, Junichi
    Yoshizawa, Akihiko
    Mori, Yukiko
    Nagayama, Satoshi
    Morosini, Paola
    Toi, Masakazu
    ANGIOGENESIS, 2012, 15 (01) : 141 - 150
  • [29] Phase II trial of neoadjuvant carboplatin and nab-paclitaxel in patients with locally advanced triple negative breast cancer
    Yuan, Y.
    Frankel, P.
    Li, M.
    Kruper, L.
    Jones, V.
    Treece, T.
    Waisman, J.
    Yim, J.
    Tumyan, L.
    Schmolze, D.
    Hurria, A.
    Yeon, C.
    Mortimer, J.
    Somlo, G.
    CANCER RESEARCH, 2019, 79 (04)
  • [30] A randomized, open-label CECOG phase II study of dose-dense FEC 75 vs FEC 90 as adjuvant therapy in early breast cancer patients
    Kahan, S.
    Spanik, S.
    Wagnerova, M.
    Skacel, T.
    Planko, B.
    Fitzthum, E.
    Lindner, E.
    Soldatenkova, V.
    Zielinski, C. C.
    Brodowicz, T.
    EJC SUPPLEMENTS, 2007, 5 (04): : 211 - 212
12345